Literature DB >> 18157729

Expression of aromatase and estrogen receptors in human adrenocortical tumors.

Luisa Barzon1, Giulia Masi, Monia Pacenti, Marta Trevisan, Francesco Fallo, Andrea Remo, Guido Martignoni, Daniela Montanaro, Vincenzo Pezzi, Giorgio Palù.   

Abstract

We recently demonstrated that adrenocortical carcinoma cells express aromatase and estrogen receptors (ERs) and that 17beta-estradiol enhances adrenocortical cell proliferation. To provide a clue to the role of estrogens in adrenal tumorigenesis, we investigated the expression profile of genes involved in sex steroid hormone production and activity in a large series of normal and neoplastic human adrenocortical tissues. Quantitative reverse transcriptase-polymerase chain reaction, Western blotting, and immunohistochemistry showed that ERalpha and ERbeta, androgen receptor (AR), and aromatase were expressed in the adrenal cortex and in adrenocortical tumors. ERbeta was the predominant ER subtype and was mainly expressed in the zona glomerulosa and fasciculata. Western blot analysis revealed the presence of a truncated form of AR in adrenocortical tissues. With respect to the normal adrenal cortex and adrenocortical adenomas, carcinomas were characterized by significantly lower ERbeta levels, ERalpha upregulation, and aromatase overexpression. ER expression correlated with expression of nuclear hormone receptors, suggesting they could be involved in ER modulation. In agreement with our in vitro findings, the results of this study suggest that estrogens, locally produced by aromatase, could enhance adrenocortical cell proliferation though autocrine/paracrine mechanisms. This study opens new perspectives on the potential use of antiestrogens and aromatase inhibitors as therapeutic agents against ACC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18157729     DOI: 10.1007/s00428-007-0542-0

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.535


  37 in total

Review 1.  Is oestrogen receptor-beta a predictor of endocrine therapy responsiveness in human breast cancer?

Authors:  Leigh C Murphy; Peter H Watson
Journal:  Endocr Relat Cancer       Date:  2006-06       Impact factor: 5.678

2.  Aromatase p450 expression in a feminizing adrenal adenoma presenting as isosexual precocious puberty.

Authors:  C Phornphutkul; T Okubo; K Wu; Z Harel; T F Tracy; H Pinar; S Chen; P A Gruppuso; G Goodwin
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

3.  Antiestrogens upregulate estrogen receptor beta expression and inhibit adrenocortical H295R cell proliferation.

Authors:  D Montanaro; M Maggiolini; A G Recchia; R Sirianni; S Aquila; L Barzon; F Fallo; S Andò; V Pezzi
Journal:  J Mol Endocrinol       Date:  2005-10       Impact factor: 5.098

4.  Expression profiles of COUP-TF, DAX-1, and SF-1 in the human adrenal gland and adrenocortical tumors: possible implications in steroidogenesis.

Authors:  H Shibata; Y Ikeda; T Mukai; K Morohashi; I Kurihara; T Ando; T Suzuki; S Kobayashi; M Murai; I Saito; T Saruta
Journal:  Mol Genet Metab       Date:  2001 Sep-Oct       Impact factor: 4.797

5.  Purification and characterization of equine testicular cytochrome P-450 aromatase: comparison with the human enzyme.

Authors:  S Moslemi; A Vibet; V Papadopoulos; L Camoin; P Silberzahn; J L Gaillard
Journal:  Comp Biochem Physiol B Biochem Mol Biol       Date:  1997-09       Impact factor: 2.231

6.  Inhibition of androgen receptor (AR) function by the reproductive orphan nuclear receptor DAX-1.

Authors:  Elin Holter; Noora Kotaja; Sari Mäkela; Leena Strauss; Silke Kietz; Olli A Jänne; Jan-Ake Gustafsson; Jorma J Palvimo; Eckardt Treuter
Journal:  Mol Endocrinol       Date:  2002-03

7.  Evidence for androgen receptor gene expression and growth inhibitory effect of dihydrotestosterone on human adrenocortical cells.

Authors:  R Rossi; M C Zatelli; A Valentini; P Cavazzini; F Fallo; L del Senno; E C degli Uberti
Journal:  J Endocrinol       Date:  1998-12       Impact factor: 4.286

8.  Profiling transcript levels for steroidogenic enzymes in fetal tissues.

Authors:  Vincenzo Pezzi; J M Mathis; William E Rainey; Bruce R Carr
Journal:  J Steroid Biochem Mol Biol       Date:  2003-11       Impact factor: 4.292

Review 9.  Loss of ERbeta expression as a common step in estrogen-dependent tumor progression.

Authors:  A Bardin; N Boulle; G Lazennec; F Vignon; P Pujol
Journal:  Endocr Relat Cancer       Date:  2004-09       Impact factor: 5.678

10.  Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence.

Authors:  Stephen J Libertini; Clifford G Tepper; Veronica Rodriguez; David M Asmuth; Hsing-Jien Kung; Maria Mudryj
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

View more
  16 in total

1.  Estrogen receptors alpha and beta in adrenal cortical neoplasia: heterogeneity and physiological implications.

Authors:  Despina Georgiadou; Theodoros N Sergentanis; Akrivi Kostopoulou; George N Zografos; George Papastratis
Journal:  Virchows Arch       Date:  2008-06-13       Impact factor: 4.064

2.  Emerging therapy for adrenocortical carcinoma.

Authors:  Rachel D Aufforth; Naris Nilubol
Journal:  Int J Endocr Oncol       Date:  2014

Review 3.  Molecular markers of adrenocortical tumors.

Authors:  Meenu Jain; Nesrin Rechache; Electron Kebebew
Journal:  J Surg Oncol       Date:  2012-04-13       Impact factor: 3.454

4.  Comparative effects of prolactin versus ACTH, estradiol, progesterone, testosterone, and dihydrotestosterone on cortisol release and proliferation of the adrenocortical carcinoma cell line H295R.

Authors:  Sukanya Jaroenporn; Chie Furuta; Kentaro Nagaoka; Gen Watanabe; Kazuyoshi Taya
Journal:  Endocrine       Date:  2008-05-17       Impact factor: 3.633

5.  Cytotoxic Effect of Progesterone, Tamoxifen and Their Combination in Experimental Cell Models of Human Adrenocortical Cancer.

Authors:  Elisa Rossini; Mariangela Tamburello; Andrea Abate; Silvia Beretta; Martina Fragni; Manuela Cominelli; Deborah Cosentini; Constanze Hantel; Federica Bono; Salvatore Grisanti; Pietro Luigi Poliani; Guido A M Tiberio; Maurizio Memo; Sandra Sigala; Alfredo Berruti
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-26       Impact factor: 5.555

6.  Current and emerging therapeutic options in adrenocortical cancer treatment.

Authors:  Antonio Stigliano; Lidia Cerquetti; Camilla Sampaoli; Barbara Bucci; Vincenzo Toscano
Journal:  J Oncol       Date:  2012-08-14       Impact factor: 4.375

7.  GPER agonist G-1 decreases adrenocortical carcinoma (ACC) cell growth in vitro and in vivo.

Authors:  Adele Chimento; Rosa Sirianni; Ivan Casaburi; Fabiana Zolea; Pietro Rizza; Paola Avena; Rocco Malivindi; Arianna De Luca; Carmela Campana; Emilia Martire; Francesco Domanico; Francesco Fallo; Giulia Carpinelli; Lidia Cerquetti; Donatella Amendola; Antonio Stigliano; Vincenzo Pezzi
Journal:  Oncotarget       Date:  2015-08-07

8.  Estrogen related receptor α (ERRα) a promising target for the therapy of adrenocortical carcinoma (ACC).

Authors:  Ivan Casaburi; Paola Avena; Arianna De Luca; Adele Chimento; Rosa Sirianni; Rocco Malivindi; Vittoria Rago; Marco Fiorillo; Francesco Domanico; Carmela Campana; Anna Rita Cappello; Federica Sotgia; Michael P Lisanti; Vincenzo Pezzi
Journal:  Oncotarget       Date:  2015-09-22

9.  Prognostic Factors for Adrenocortical Carcinoma Outcomes.

Authors:  Claudia Scollo; Marco Russo; Maria Antonietta Trovato; Daniela Sambataro; Dario Giuffrida; Mario Manusia; Giulia Sapuppo; Pasqualino Malandrino; Riccardo Vigneri; Gabriella Pellegriti
Journal:  Front Endocrinol (Lausanne)       Date:  2016-07-25       Impact factor: 5.555

10.  Role of Scaffold Protein Proline-, Glutamic Acid-, and Leucine-Rich Protein 1 (PELP1) in the Modulation of Adrenocortical Cancer Cell Growth.

Authors:  Arianna De Luca; Paola Avena; Rosa Sirianni; Adele Chimento; Francesco Fallo; Catia Pilon; Ivan Casaburi; Vincenzo Pezzi
Journal:  Cells       Date:  2017-11-07       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.